N/A
N=88
Comparing Two Training Methods for Opioid Wizard
Opioid-use Disorder · Opioid Dependence · Attitude of Health Personnel
Bottom Line
View on ClinicalTrials.gov: NCT04867382 ↗Enrolled (actual)
88
Serious AEs
—
Results posted
Dec 2022
Primary outcome: Primary: Difference, Disdain, and Blame Scales — 4.1; 4.3 score on a scale — p=.63
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Online training (Behavioral)
- Age
- Pediatric, Adult, Older Adult
- Sex
- All
- Sponsor
- HealthPartners Institute
- Primary completion
- Sep 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Difference, Disdain, and Blame Scales |
4.1; 4.3 | .63 |
| SECONDARY Intentions to Get Waivered to Prescribe Buprenorphine. |
2.3; 2.1 | 0.27 |
| SECONDARY Intentions to Prescribe Buprenorphine Should a Waiver no Longer be Required. |
3.2; 3.0 | .37 |
| SECONDARY Opioid Wizard Use |
3; 4 | .12 |
Summary
The prevalence of opioid use disorder (OUD) and opioid-related deaths has risen dramatically in recent years. Effective treatments, including medications for opioid use disorder (MOUDs; e.g., buprenorphine-naloxone and methadone) are under-utilized. There are few evidence-based interventions for changing attitudes toward Opioid Use Disorder (OUD) in the general public and especially among healthcare clinicians. This study proposed an innovative intervention to change attitudes of Primary Care Clinicians (PCCs) toward persons with OUD. Study participants were stratified into one of two online learning courses: the intervention training was compared with an attention-control training.
Eligibility Criteria
Inclusion Criteria
- Primary Care Clinician: Had to be a family physician, general internist, adult-care non-obstetric nurse practitioner, or a physician assistant
- Had to practice at a study-eligible primary care clinic already involved in the main study intervention arm
Exclusion Criteria
PCCs were ineligible to participate if they had fewer than 5 eligible patient encounters between Sep 2020 and Feb 2021.
Data sourced from ClinicalTrials.gov (NCT04867382). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.